GE医疗
GEHC
69.57
-0.78
-1.11%
GE医疗
US · GEHC
#689 按市值排名
上市于 2022
69.57
-0.78
-1.11%
实时 - 追踪5344个代码 - 心跳于141秒前
· 2026-10-16 19:56
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了7家。
- 机构持股总比例上升了2.0个百分点。
机构持股
- 机构持股比例
- 93.72% +2.04pp
- 机构数量
- 1,450 -7
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund80.61%
Public Company3.55%
Hedge Fund3.18%
Government Pension Fund1.98%
Private Company1.53%
Sovereign Wealth Fund1.32%
VC/PE Fund0.80%
Family Office/Trust0.24%
Individual/Insider0.22%
Other6.58%
主要股东 截至 2026-07-31
Dodge & Cox
10.48% · 47.33M 股
BlackRock
8.30% · 37.47M 股
Vanguard Capital Management, LLC
7.15% · 32.28M 股
State Street Global Advisors
4.62% · 20.86M 股
Vanguard Portfolio Management, LLC
4.49% · 20.28M 股
Invesco Capital Management LLC
3.52% · 15.91M 股
Harris Associates L.P.
3.39% · 15.33M 股
Barrow, Hanley, Mewhinney & Strauss, LLC
2.98% · 13.46M 股
Geode Capital Management, LLC
2.85% · 12.87M 股
Hotchkis and Wiley Capital Management, LLC
2.71% · 12.25M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 31次买入 · 16次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| H. Culp | Chairperson | 0.11% |
| Peter Arduini | Chief Executive Officer | 0.03% |
| Frank Jimenez | General Counsel | 0.02% |
| Taha Kass-Hout | Chief Technology Officer | 0.01% |
| James Saccaro | Vice President | 0.01% |
| Kevin O’Neill | CEO of Pharmaceutical Diagnostics | 0.00% |
| Kenneth Stacherski | Chief Global Supply Chain & Service Officer | 0.00% |
| Anne Madden | Independent Director | 0.00% |
| Roland Rott | CEO of Ultrasound | 0.00% |
| Catherine Estrampes | President and CEO of US & Canada | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-13 | William Grogan | Chief Financial Officer | Other Acquisition | +75,096 | -- |
| 2026-09-13 | William Grogan | Chief Financial Officer | Other Derivative Acquisition | +31,877 | $64.25 |
| 2026-09-02 | Peter Arduini | Chief Executive Officer | Sale to Issuer | -6,303 | $70.56 |
| 2026-09-02 | George Newcomb | Controller & Chief Accounting Officer | Sale to Issuer | -112 | $70.56 |
| 2026-09-02 | Frank Jimenez | General Counsel | Sale to Issuer | -1,480 | $70.56 |
| 2026-09-02 | Adam Holton | Chief Human Resources Officer | Sale to Issuer | -673 | $70.56 |
| 2026-09-02 | Catherine Estrampes | President and CEO of US & Canada | Sale to Issuer | -508 | $70.56 |
| 2026-09-02 | Philip Rackliffe | President & CEO of Image Guided Therapies & Ultrasound | Sale to Issuer | -798 | $70.56 |
| 2026-09-02 | Kevin O’Neill | CEO of Pharmaceutical Diagnostics | Sale to Issuer | -718 | $70.56 |
| 2026-09-02 | Taha Kass-Hout | Chief Technology Officer | Sale to Issuer | -1,502 | $70.56 |
| 2026-08-31 | Peter Arduini | Chief Executive Officer | Sale to Issuer | -11,515 | $71.23 |
| 2026-08-31 | Frank Jimenez | General Counsel | Sale to Issuer | -3,131 | $71.23 |
| 2026-08-31 | Adam Holton | Chief Human Resources Officer | Sale to Issuer | -659 | $71.23 |
| 2026-08-31 | Jeannette Bankes | President & CEO of Patient Care Solutions | Sale to Issuer | -1,064 | $71.23 |
| 2026-08-31 | Philip Rackliffe | President & CEO of Image Guided Therapies & Ultrasound | Sale to Issuer | -856 | $71.23 |
| 2026-08-31 | Taha Kass-Hout | Chief Technology Officer | Sale to Issuer | -2,940 | $71.23 |
| 2026-08-14 | Adam Holton | Chief Human Resources Officer | Sale to Issuer | -1,360 | $73.69 |
| 2026-05-21 | Kevin Lobo | Director | Open Market Acquisition | +10,000 | $64.18 |
| 2026-05-14 | Jeannette Bankes | President & CEO of Patient Care Solutions | Sale to Issuer | -5,535 | $62.67 |
| 2026-05-14 | Philip Rackliffe | President & CEO of Image Guided Therapies & Ultrasound | Other Acquisition | +16,458 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:56:18 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
GE医疗 讨论区 0 条评论